8.02
Nutriband Inc stock is traded at $8.02, with a volume of 23,974.
It is up +1.91% in the last 24 hours and up +23.38% over the past month.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
See More
Previous Close:
$7.87
Open:
$7.86
24h Volume:
23,974
Relative Volume:
0.51
Market Cap:
$84.59M
Revenue:
$2.09M
Net Income/Loss:
$-5.28M
P/E Ratio:
-11.97
EPS:
-0.67
Net Cash Flow:
$-3.64M
1W Performance:
+2.82%
1M Performance:
+23.38%
6M Performance:
+70.28%
1Y Performance:
+33.89%
Nutriband Inc Stock (NTRB) Company Profile
Name
Nutriband Inc
Sector
Industry
Phone
407 377-6695
Address
121 S. ORANGE AVE., ORLANDO
Compare NTRB with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
NTRB
Nutriband Inc
|
8.02 | 84.59M | 2.09M | -5.28M | -3.64M | -0.67 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Nutriband Inc Stock (NTRB) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-22-25 | Initiated | Noble Capital Markets | Outperform |
Nutriband Inc Stock (NTRB) Latest News
Nutriband and Kindeva Complete Commercial Manufacturing Process Scale-Up for Aversa?? Fentanyl Abuse Deterrent Fentanyl Patch - MarketScreener
Nutriband and Kindeva Complete Commercial Manufacturing - GlobeNewswire
Nutriband and Kindeva Complete Commercial Manufacturing Process - GuruFocus
Nutriband (NTRB) Advances Aversa Fentanyl Manufacturing Process | NTRB Stock News - GuruFocus
Nutriband, Kindeva complete commercial manufacturing process scale-up for Aversa - TipRanks
Revolutionary Abuse-Deterrent Fentanyl Patch Completes Manufacturing Scale-up: $200M Market Potential - Stock Titan
Nutriband Inc. Reports Significant Revenue Growth and Advances in AVERSA Fentanyl Development - citybuzz -
(NTRB) Proactive Strategies - news.stocktradersdaily.com
Nutriband (NASDAQ: NTRB) Secures U.S. Patent for Abuse-Deterrent Transdermal Technology - The Globe and Mail
Nutriband Inc. Secures U.S. Patent for Innovative Abuse-Deterrent Transdermal Technology - citybuzz -
Nutriband secures US patent for abuse deterrent patch technology By Investing.com - Investing.com South Africa
Nutriband issued U.S. patent for transdermal abuse deterrent technology - TipRanks
Nutriband Announces U.S. Patent Issued for Its Transdermal Abuse Deterrent Technology - The Manila Times
Nutriband secures US patent for abuse deterrent patch technology - Investing.com Australia
Nutriband Announces U.S. Patent Issued for Its Transdermal Abuse Deterrent Technology | NTRB Stock News - GuruFocus
Nutriband (NTRB) Secures Patent for Abuse Deterrent Technology | NTRB Stock News - GuruFocus
Nutriband Secures Game-Changing Patent for First-Ever Abuse-Deterrent Fentanyl Patch Technology - Stock Titan
Nutriband (NASDAQ: NTRB) Advances Abuse-Deterrent Buprenorphine Therapy with AVERSA Technology - Barchart.com
Nutriband (NASDAQ: NTRB): A Relentless Mission Rooted in Purpose, Innovation, and Shareholder Value - The Globe and Mail
Nutriband Inc. Pioneers Abuse-Deterrent Technology with AVERSA, Targets $800 Million Market Potential - citybuzz -
Nutriband Inc. to present at the 2025 Noble Capital Markets Virtual Equity Conference - GlobeNewswire
Nutriband (NASDAQ: NTRB) to Present at Noble Capital Markets Emerging Growth Virtual Conference - The Globe and Mail
Nutriband CEO Reveals Growth Strategy: Exclusive Virtual Presentation at Noble Capital Conference - Stock Titan
Nutriband reports Q1 revenue up 63% y/y at $667K - TipRanks
Nutriband First Quarter 2026 Earnings: EPS Beats Expectations - Yahoo Finance
Nutriband (NASDAQ: NTRB) Posts Record Q1 Revenue, Advances AVERSA Fentanyl Development - The Globe and Mail
Nutriband Inc. Reports Revenue Results for the First Quarter Ended April 30, 2025 - MarketScreener
Nutriband Inc. Provides Update on the Development of AVERSA Fentanyl - MarketScreener
Nutriband (NTRB) Expands Kinesiology Tape Production and Advances Drug Delivery Solutions | NTRB Stock News - GuruFocus
Nutriband Inc. Quarterly Report Highlights Record Revenue for Q1, 2025 up 63% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl - The Manila Times
Nutriband Inc. Quarterly Report Highlights Record Revenue - GlobeNewswire
Nutriband Q1 Revenue Surges 63% as AVERSA Fentanyl Development Advances | NTRBW Stock News - Stock Titan
Nutriband Inc. (NTRB) reports Q1 loss, misses revenue estimates - FXStreet
Nutriband Inc. (NTRB) Reports Q1 Loss, Misses Revenue Estimates - MSN
NutriBand Inc. SEC 10-Q Report - TradingView
(NTRB) Investment Analysis - news.stocktradersdaily.com
Nutriband Addresses Opioid Pain Management Challenges with Innovative Transdermal Solution - citybuzz -
Nutriband (NASDAQ: NTRB) CEO Highlights Transdermal Pain Solution on BioMedWire Podcast - Barchart.com
IBN Announces Latest Episode Of The Biomedwire Podcast Featuring Gareth Sheridan, CEO Of Nutriband Inc. - marketscreener.com
IBN Announces Latest Episode of The BioMedWire Podcast Featuring Gareth Sheridan, CEO of Nutriband Inc. - GlobeNewswire
Nutriband (NASDAQ: NTRB) Charts Path To Commercialization - Barchart.com
Stocks in play: Brookfield Corporation - The Globe and Mail
Nutriband Advances Opioid Pain Patch Technology with Strategic Partnership - citybuzz -
Concern Rises over Market Valutions and Structural Vibrations - The Globe and Mail
(NTRB) On The My Stocks Page - news.stocktradersdaily.com
Nutriband (NASDAQ: NTRB) Strengthens Pharma Footprint Through Key Alliances - Barchart.com
Nutriband Expands Market Presence Through Strategic Health Industry Partnerships - citybuzz -
Why Isn't Palantir's Stock Taking Off After Another Strong Quarter? - The Globe and Mail
Nutriband (NASDAQ: NTRB) Pioneers Innovative Approach to Opioid Crisis with Game-Changing Transdermal Patch - Barchart.com
Nutriband Develops Innovative Abuse-Deterrent Fentanyl Patch Amid Opioid Crisis Regulatory Changes - citybuzz -
Nutriband (NASDAQ: NTRB) Innovating Abuse-Deterrent Drug Delivery in a Shifting Opioid Landscape - Barchart.com
Nutriband Inc Stock (NTRB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):